Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethinylestradiol/gestodene transdermal - Bayer Schering Pharma

Next Previous
X
Search
Drug Profile

Ethinylestradiol/gestodene transdermal - Bayer Schering Pharma

Alternative Names: APLEEK; BAY86-5016; Estrogen/gestagen transdermal; Ethinylestradiol/gestodene transparent low dose contraceptive patch - Bayer HealthCare; FC Patch Fidencia; FC Patch Low; FC-patch; Fertility Control patch; Gestagen/estrogen transdermal; Gestodene/EE Patch; Gestodene/ethinylestradiol transdermal; Lisvy

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Gedeon Richter
  • Class Alkylated estrogenic steroids; Norpregnatrienes; Norpregnenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 05 Jul 2019 Ethinylestradiol/gestoden is not yet available for Pregnancy (Prevention) in Spain, Italy, Italy, Netherlands, Germany, Lithuania, Denmark, Slovenia, Finland, Belgium, Ireland, Slovakia, Romania, Portugal, Iceland, Czech Republic, Malta, Greece, Austria (Transdermal)
  • 05 Jul 2019 Launched for Pregnancy (Prevention) in Spain, Czech Republic, Hungary, Spain prior July 2019 (Transdermal)
  • 06 Aug 2018 Luye Pharma acquires global rights for Ethinylestradiol/gestodene from Bayer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top